Recombinant alpha 2a interferon-an effective maintenance agent in essential thrombocythaemia

Francis J. Giles*, Cathy C. Anderson, Ian R. Grant, A. Victor Hoffbrand, Atul B. Mehta, Samuel J. Machin, Anthony H. Goldstone

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Recombinant alpha 2a, 2b and 2c interferons have been shown to be effective short-term agents in essential thrombocythaemia and thrombocythaemia associated with the other myeloproliferative disorders, including chronic granulocytic leukaemia, polycythaemia rubra vera and myelofibrosis. Few data exist on the use of the recombinant interferons as maintenance agents in patients with thrombocythaemia. We report on a cohort of 22 previously untreated patients, with essential thrombocythaemia, treated with recombinant alpha 2a interferon maintenance therapy for a minimum period of 6 months. Effective long-term control of platelet counts, without evidence of haematological toxicity, was achieved in 19 of 22 patients. No objective haemorrhagic or thrombotic event occurred in 298 patient months of interferon therapy. Three patients discontinued alpha interferon therapy due to adverse side-effects. Alpha 2a interferon is an effective maintenance agent in essential thrombocythaemia.

Original languageEnglish (US)
Pages (from-to)103-107
Number of pages5
JournalLeukemia and Lymphoma
Issue number2
StatePublished - 1990


  • Alpha interferon
  • Essential thrombocythaemia
  • Maintenance therapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Recombinant alpha 2a interferon-an effective maintenance agent in essential thrombocythaemia'. Together they form a unique fingerprint.

Cite this